Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 16, 1996

View Archived Issues

New antihypertensive agents from Banyu

Distamycin analogues claimed by Mitsui Toatsu

New antitussive agent from Snow Brand Milk Products

Antiinflammatory glycolipid compounds from Nissin Food Products

Antiallergic/antiasthmatic compounds disclosed by Dainippon Ink

Eisai describes selective dopamine D3 antagonists

Novel anticancer agents from Sankyo

Toray reports peptides for toxic shock syndrome

British Biotech reports new MMP inhibitors

New ET-1 inhibitors from Ciba-Geigy

Scotia files EF27

University of Alberta discovers new chemokine-binding protein

Neurogen and Pfizer extend GABA-based collaboration

Affymax researches potential malaria vaccines

LXR Biotechnology/Boehringer Mannheim enter breast and prostate cancer collaboration

Oncor expands marketing of breast cancer test

SKB reports new vaccine compositions

Human growth hormone products recommended for approval

Advanced Polymer Systems to supply Johnson & Johnson with Microsponge-entrapped AHAs

New antisense compounds reported by French investigators

Alanex and Novo Nordisk expand diabetes research collaboration

MedImmune files IND for HPV vaccine candidate

New bile acid transporter inhibitors in preclinical testing at Searle

Acea describes candidate neuroprotectant

Glaxo Wellcome granted license to Cellegy orphan drug

Oncogene Science and Bayer initiate cancer diagnostics collaboration

CRC and Cortecs to develop cancer diagnostic tests

Terrapin Technologies obtains rights to Walter Reed compound library

Epic receives patent coverage for core drug delivery technology

Celox Laboratories' ViaStem receives patent coverage

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...